Why do insurance carriers scrutinize GLP-1 and semaglutide compounding so closely?

GLP-1 compounding is a high-scrutiny insurance class for a combination of reasons. The regulatory picture around compounded semaglutide and tirzepatide has shifted with FDA shortage-list changes, which affect when and whether mass compounding is permitted, and enforcement attention on the space is significant. Demand has grown very fast, drawing new and sometimes less-experienced operators into the market, and there is an active litigation and adverse-event climate around weight-management drugs.

For underwriters, that combination means both higher potential claim frequency and severity and more regulatory uncertainty. As a result, fewer carriers will write the exposure, and those that do apply closer underwriting - looking at the operator's licensure, sourcing, sterile-compounding compliance, clinical protocols, and prior claims.

The practical implication is that a GLP-1 operator should expect to demonstrate strong compliance and disclose the full operation to get a fast, real answer, because a market that writes general compounding may still decline the GLP-1 angle specifically.